Enfusion, Inc.
ENFNInactive ticker- Industry
- Services-Prepackaged Software
- SEC CIK
- 0001868912
No open-market purchases or sales by Enfusion, Inc. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
This ticker is no longer on the SEC's list of tickers: the company may have been delisted, or the ticker has changed.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q2 2026
- 13F value
- $0
- Reported value at the end of Q2 2026
- Superinvestors holding
- 0
- At the end of Q2 2026
Superinvestors holding ENFN, Q2 2026
No superinvestor reported holding ENFN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Enfusion, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 7, 2025 (view filing)6:15 PM ET | Mar 6 | 1 day | Movchan Oleg and 1 otherChief Executive Officer | SSaleClass A Common Stock | −11.5K | $11.39 | −$130.5K | −1.8%631.8K after | |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Bastone BronwenChief People Officer | SSaleClass A Common Stock | −3.13K | $11.38 | −$35.6K | −1.4%221.9K after | |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Campobasso MatthewGeneral Counsel | SSaleClass A Common Stock | −1.70K | $11.38 | −$19.3K | −2.3%70.9K after | |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Pawar NealChief Operating Officer | SSaleClass A Common Stock | −14.6K | $11.38 | −$165.7K | −1.2%1.22M after | |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Gutowski ValeriaChief Accounting Officer | SSaleClass A Common Stock | −542 | $11.38 | −$6.17K | −1.1%47.6K after | |
| Mar 7, 2025 (view filing) | Mar 5 | 2 days | Herring BradleyChief Financial Officer | SSaleClass A Common Stock | −4.64K | $11.38 | −$52.9K | −1.4%324.7K after | |
| Mar 6, 2025 (view filing) | Mar 4 | 2 days | Gutowski ValeriaChief Accounting Officer | SSaleClass A Common Stock | −1.23K | $11.37 | −$14.0K | −2.5%48.2K after | |
| Mar 5, 2025 (view filing)6:20 PM ET | Mar 3 | 2 days | Movchan Oleg and 1 otherChief Executive Officer | SSaleClass A Common Stock | −2.79K | $11.48 | −$32.0K | −0.4%643.3K after | |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Gutowski ValeriaChief Accounting Officer | SSaleClass A Common Stock | −219 | $11.48 | −$2.51K | −0.4%49.4K after | |
| Mar 5, 2025 (view filing) | Mar 3 | 2 days | Pawar NealChief Operating Officer | SSaleClass A Common Stock | −2.77K | $11.48 | −$31.8K | −0.2%1.23M after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Enfusion, Inc. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding ENFN in 13F filings for Q2 2026.